United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have been given a consensus rating of “Moderate Buy” by the eleven analysts that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $509.50.

A number of research analysts have recently issued reports on the company. Wells Fargo & Company lifted their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research note on Wednesday, November 19th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a report on Wednesday, October 29th. HC Wainwright raised their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Royal Bank Of Canada lifted their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $470.43, for a total transaction of $10,584,675.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold 519,364 shares of company stock valued at $248,945,392 over the last 90 days. 10.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Torren Management LLC purchased a new stake in United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. Wilmington Savings Fund Society FSB raised its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the last quarter. Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $48,000. Finally, Chung Wu Investment Group LLC acquired a new stake in United Therapeutics in the 2nd quarter worth approximately $29,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Up 1.2%

Shares of UTHR stock opened at $475.00 on Tuesday. The firm has a market cap of $20.45 billion, a price-to-earnings ratio of 18.00, a PEG ratio of 2.50 and a beta of 0.85. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $519.99. The company’s 50 day moving average is $487.22 and its 200 day moving average is $423.14.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.